BR9206398A - Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos - Google Patents

Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos

Info

Publication number
BR9206398A
BR9206398A BR9206398A BR9206398A BR9206398A BR 9206398 A BR9206398 A BR 9206398A BR 9206398 A BR9206398 A BR 9206398A BR 9206398 A BR9206398 A BR 9206398A BR 9206398 A BR9206398 A BR 9206398A
Authority
BR
Brazil
Prior art keywords
promote
release
humans
animal
recovery
Prior art date
Application number
BR9206398A
Other languages
English (en)
Inventor
Cyril Y Bowers
David Coy
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of BR9206398A publication Critical patent/BR9206398A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BR9206398A 1991-08-22 1992-08-20 Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos BR9206398A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/748,350 US5663146A (en) 1991-08-22 1991-08-22 Polypeptide analogues having growth hormone releasing activity
PCT/US1992/007026 WO1993004081A1 (en) 1991-08-22 1992-08-20 Peptides having growth hormone releasing activity

Publications (1)

Publication Number Publication Date
BR9206398A true BR9206398A (pt) 1994-12-27

Family

ID=25009088

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9206398A BR9206398A (pt) 1991-08-22 1992-08-20 Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
BR1100309-0A BR1100309A (pt) 1991-08-22 1997-04-22 Peptìdeo e composição farmacêutica para promover a liberação de nìveis de hormÈnio de crescimento em animais

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR1100309-0A BR1100309A (pt) 1991-08-22 1997-04-22 Peptìdeo e composição farmacêutica para promover a liberação de nìveis de hormÈnio de crescimento em animais

Country Status (26)

Country Link
US (2) US5663146A (pt)
EP (1) EP0605484B1 (pt)
JP (1) JP3179489B2 (pt)
KR (1) KR100247212B1 (pt)
CN (1) CN1035256C (pt)
AT (1) ATE172742T1 (pt)
AU (1) AU666673B2 (pt)
BG (1) BG62655B1 (pt)
BR (2) BR9206398A (pt)
CA (1) CA2116120C (pt)
CZ (1) CZ293281B6 (pt)
DE (1) DE69227462T2 (pt)
DK (1) DK0605484T3 (pt)
ES (1) ES2124263T3 (pt)
FI (2) FI120095B (pt)
HU (1) HU223664B1 (pt)
IL (1) IL102848A (pt)
MX (1) MX9204861A (pt)
NO (1) NO314695B1 (pt)
NZ (1) NZ244034A (pt)
PL (1) PL169562B1 (pt)
RO (1) RO112507B1 (pt)
RU (1) RU2126014C1 (pt)
SK (1) SK282895B6 (pt)
WO (1) WO1993004081A1 (pt)
ZA (1) ZA926337B (pt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160786A1 (en) 1993-05-14 1994-11-24 James C. Marsters, Jr. Ras farnesyl transferase inhibitors
IL112111A (en) * 1993-12-23 2000-07-16 Novo Nordisk As Peptides having growth hormone releasing properties and pharmaceutical compositions containing them
HU224345B1 (hu) * 1993-12-23 2005-08-29 Novo Nordisk A/S. Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
CA2224434A1 (en) * 1995-06-22 1997-01-09 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0907643B1 (en) * 1996-04-24 2003-01-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
PL341707A1 (en) 1998-01-16 2001-04-23 Novo Nordisk As Compounds exibiting growth hormone releasing properties
WO1999039730A1 (fr) * 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
JP2002520011A (ja) 1998-07-13 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド 成長ホルモン分泌促進物質関連受容体および核酸
JP2002522058A (ja) 1998-08-10 2002-07-23 メルク・アンド・カンパニー・インコーポレーテッド イヌ成長ホルモン分泌促進物質受容体
AU5671099A (en) * 1998-08-14 2000-03-06 The Administrators Of The Tulane Eductional Fund Compounds having growth hormone releasing activity
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7022677B1 (en) 1999-02-18 2006-04-04 Kaken Pharmaceutical Co., Ltd. Amide derivatives as growth hormone secretagogues
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
AU772752B2 (en) 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US20040192593A1 (en) 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
US7022311B1 (en) * 1999-10-12 2006-04-04 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) * 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
CN1491233A (zh) 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
CN100417419C (zh) * 2001-10-26 2008-09-10 贝勒医学院 改变个体的瘦体重和骨特性的组合物和方法
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
MXPA04005713A (es) 2001-12-11 2005-06-06 Baylor College Medicine Complemento de la hormona de liberacion de la hormona de crecimiento para tratar sujetos cronicamente enfermos.
US7015219B2 (en) 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
CA2475273A1 (en) * 2002-02-07 2003-08-14 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7381730B2 (en) 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
AU2003220441A1 (en) * 2002-04-09 2003-10-27 Eli Lilly And Company Dipeptidic growth hormone secretagogues
AU2003225305A1 (en) 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003259340A1 (en) 2002-08-23 2004-03-11 Gestion Univalor Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004067719A2 (en) * 2003-01-28 2004-08-12 Advisys, Inc. Growth hormone releasing hormone (ghrh) for use in reducing culling in herd animals
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005016964A2 (en) * 2003-08-04 2005-02-24 Advisys, Inc. Canine specific growth hormone releasing hormone
AU2003272814A1 (en) 2003-10-02 2005-05-19 Ibrahim Al-Habdan Peptide for promoting healing of fractures
EP1711187B1 (en) 2003-12-31 2010-05-12 VGX Pharmaceuticals, LLC Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
WO2005073371A2 (en) * 2004-01-20 2005-08-11 Advisys, Inc. Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide
US20050164952A1 (en) * 2004-01-23 2005-07-28 Vital Pharmaceuticals, Inc. Delivery system for growth hormone releasing peptides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
MX2007000893A (es) * 2004-07-23 2007-04-18 Advisys Inc La hormona liberadora de hormona de crecimiento mejora la respuesta inmune inducida por la vacunacion.
EP1781311A4 (en) 2004-08-18 2010-02-17 Elixir Pharmaceuticals Inc WACHSTUMSHORMONSEKRETAGOGE
US7456188B1 (en) 2005-04-28 2008-11-25 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
EP2425715B1 (en) 2005-08-31 2014-03-05 University of Tennessee Research Foundation Treating symptoms of renal disease with selective androgen receptor modulators (SARM)
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
EA018258B1 (ru) 2006-07-12 2013-06-28 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенный ациланилид и содержащие его композиции и способы лечения
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
ES2558517T3 (es) 2006-08-02 2016-02-04 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
PL2054049T3 (pl) 2006-08-24 2016-11-30 Podstawione acyloanilidy i sposoby ich stosowania
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2008134828A2 (en) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Tissue degeneration protection
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
KR102122941B1 (ko) 2012-07-13 2020-06-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP6262661B2 (ja) 2012-10-24 2018-01-17 第一三共株式会社 筋萎縮性側索硬化症治療剤
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
MX2021015468A (es) 2019-06-27 2022-01-24 Cytokinetics Inc Polimorfos de 1-(2-((((trans)-3-fluoro-1-(3-fluoropiridin-2-il)cic lobutil)metil)amino)pirimidin-5-il)-1h-pirrol-3-carboxamida.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) * 1979-03-30 1984-10-09 Frank A. Momany Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4410513A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
AU549053B2 (en) * 1981-12-28 1986-01-09 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US4880777A (en) * 1987-09-01 1989-11-14 Eastman Kodak Company Synthetic peptides having growth hormone releasing activity
WO1989007111A1 (en) * 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) * 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
JPH03504245A (ja) * 1988-05-11 1991-09-19 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
EP0540626A1 (en) 1990-07-24 1993-05-12 Eastman Chemical Company Process for synthesizing peptides
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity

Also Published As

Publication number Publication date
BR1100309A (pt) 2000-08-01
FI20050467A (fi) 2005-05-02
AU2541692A (en) 1993-03-16
DE69227462D1 (de) 1998-12-03
ES2124263T3 (es) 1999-02-01
CN1035256C (zh) 1997-06-25
AU666673B2 (en) 1996-02-22
NO940592D0 (no) 1994-02-21
RO112507B1 (ro) 1997-10-30
FI120691B (fi) 2010-01-29
CN1073684A (zh) 1993-06-30
JPH07507039A (ja) 1995-08-03
IL102848A0 (en) 1993-01-31
BG62655B1 (bg) 2000-04-28
KR100247212B1 (ko) 2000-03-15
HU223664B1 (hu) 2004-11-29
EP0605484B1 (en) 1998-10-28
FI940807A0 (fi) 1994-02-21
FI120095B (fi) 2009-06-30
CZ293281B6 (cs) 2004-03-17
EP0605484A1 (en) 1994-07-13
SK20494A3 (en) 1994-10-05
HU9400495D0 (en) 1994-05-30
SK282895B6 (sk) 2003-01-09
CA2116120A1 (en) 1993-02-23
DK0605484T3 (da) 1999-07-05
WO1993004081A1 (en) 1993-03-04
NZ244034A (en) 1995-08-28
PL169562B1 (pl) 1996-08-30
CA2116120C (en) 2002-12-03
NO314695B1 (no) 2003-05-05
RU2126014C1 (ru) 1999-02-10
BG98489A (bg) 1995-02-28
MX9204861A (es) 1994-06-30
HUT69178A (en) 1995-08-28
US5663146A (en) 1997-09-02
ATE172742T1 (de) 1998-11-15
IL102848A (en) 1998-04-05
CZ40094A3 (en) 1994-11-16
DE69227462T2 (de) 1999-04-08
US5776901A (en) 1998-07-07
FI940807A (fi) 1994-02-21
ZA926337B (en) 1993-04-22
JP3179489B2 (ja) 2001-06-25
NO940592L (no) 1994-04-14

Similar Documents

Publication Publication Date Title
BR9206398A (pt) Peptídio, processo para promover a liberação de níveis de hormônio de crescimento em um animal, composição farmacêutica, processos para promover a liberação e elevação de níveis de hormônio de crescimento no sangue, para tratar nanismo pituitário hipotalâmico, osteoporose ou queimaduras, para promover a cicatrização de feridas, a recuperação de cirurgias ou recuperação de doenças debilitantes agudas/crônicas, para prevenir ou reduzir caquexia em pacientes com câncer, para promover o anabolismo e/ou evitar catabolismo em seres humanos, para aumentar o músculo em um animal e/ou diminuir a gordura do corpo, para melhorar o padrão de lipídios no soro em seres humanos, e para preparar compostos
Laato et al. Stimulation of wound healing by epidermal growth factor. A dose-dependent effect.
KR0138658B1 (ko) 생물학적활성폴리펩티드를포함하는질내투여용약제학적조성물
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
SE8902638L (sv) Stabiliserade protein- eller peptidkonjugat
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
Dudley et al. Facilitation of lordosis in female rats by CNS-site specific infusions of an LH-RH fragment, Ac-LH-RH-(5–10)
SE9702401D0 (sv) Pharmaceutical use
US20020082196A1 (en) Peptides with physiological activity
CN1209750A (zh) 由lhrh类似物和抗***构成的联合药物制剂用以治疗妇科疾病
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
MXPA03008666A (es) Uso de antagonistas de lhrh para el tratamiento de demencia y enfermedades neurodegenerativas con dosis intermedias.
DE3880587D1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
HUT74275A (en) Process for treatment of rheumatoid arthritis
WO2018216974A2 (ko) 보툴리눔 독소 및 히알루론산을 포함하는 족부통증 질환 치료용 약학적 조성물 및 이를 이용한 족부통증 질환 치료방법
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
BR9917605A (pt) Composição substituta de plasma
EP3562501A1 (en) Neuromuscular toxin for use in treating an abnormality of the first metatarsophalangeal joint of a foot
SU1560214A1 (ru) Способ лечени фантомных болей

Legal Events

Date Code Title Description
EE Request for examination
FA Application withdrawn
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/60 (2006.01)